FDA approves Sage's postpartum depression therapy

Sage gained FDA approval for Zulresso brexanolone Tuesday, making it the first drug specifically indicated to treat postpartum depression.

Sage Therapeutics Inc. (NASDAQ:SAGE) told BioCentury the average

Read the full 268 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE